GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sera Prognostics Inc (NAS:SERA) » Definitions » Capex-to-Operating-Income

SERA (Sera Prognostics) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Sera Prognostics's Capital Expenditure for the three months ended in Dec. 2024 was $-0.06 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-9.42 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Sera Prognostics Capex-to-Operating-Income Historical Data

The historical data trend for Sera Prognostics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics Capex-to-Operating-Income Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Sera Prognostics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sera Prognostics's Capex-to-Operating-Income

For the Medical Devices subindustry, Sera Prognostics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's Capex-to-Operating-Income falls into.


;
;

Sera Prognostics Capex-to-Operating-Income Calculation

Sera Prognostics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.101) / -36.635
=N/A

Sera Prognostics's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.061) / -9.423
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sera Prognostics  (NAS:SERA) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Sera Prognostics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sera Prognostics Business Description

Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Executives
Mansoor Raza Mirza director C/O KARYOPHARM THERAPEUTICS INC., 2 MERCER ROAD, NATICK MA 01760
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Joshua Phillips director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Douglas Fisher officer: Chief Business Officer 587 PATROL RD, WOODSIDE CA 94062
Gregory C Critchfield director, officer: Chief Executive Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Blue Ox Healthcare Partners Sp, Llc 10 percent owner 135 E. 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Ii, Llc 10 percent owner 135 E 57TH STREET, 23RD FLOOR, NEW YORK NY 10022